Lichenoid granulomatous dermatitis revisited: A retrospective case series - 11/10/19
Abstract |
Background |
Lichenoid granulomatous dermatitis (LGD) is an uncommon reaction pattern for which clinical correlates can be difficult to establish. LGD combines vacuolar degeneration with variable types of granulomas.
Objective |
To determine clinical correlates of LGD.
Methods |
The laboratory information systems at the University of Florida, the Medical College of Wisconsin, and Inform Diagnostics Research Institute were queried to identify 56 cases of LGD. Cases were reviewed for information regarding eosinophils, plasma cells, deep perivascular infiltrates, granuloma subtype, parakeratosis, epidermal atrophy, psoriasiform epidermal changes, pseudoepitheliomatous hyperplasia, periadnexal inflammation, vasculitis, and red blood cell extravasation.
Results |
The most common clinical correlates were drug eruption (39.3%, n = 22) and lichenoid keratosis (19.6%, n = 11). Tattoo reaction, postherpetic dermatitis, and scabies or postscabietic dermatitis each accounted for 7.1% (n = 4) of cases. Pigmented purpuric dermatosis and lichen striatus each accounted for 5.4% (n = 3) of cases. Dermal eosinophils (P = .005) and psoriasiform epidermal changes (P = .055) were associated with drug hypersensitivity. Perineural (P = .049) and perifollicular (P = .003) inflammation were associated with tattoo reaction and postherpetic dermatitis. Red blood cell extravasation was helpful in cases of pigmented purpuric dermatosis (P = .049).
Limitations |
This study is limited by its retrospective nature and statistical power.
Conclusion |
Dermal eosinophilia, psoriasiform epidermal changes, periadnexal inflammation, and red blood cell extravasation might aid in the clinical diagnosis of patients with LGD.
Le texte complet de cet article est disponible en PDF.Key words : drug eruption, giant cell lichenoid dermatitis, granulomatous dermatitis, lichenoid dermatitis, lichenoid granulomatous dermatitis, postherpetic dermatitis
Abbreviations used : CPC, CTCL, DIH, LGD, TH1, TH2
Plan
Funding sources: Supported by the National Center for Advancing Translational Sciences of the National Institutes of Health, United States under award number UL1TR001427. |
|
Conflicts of interest: None disclosed. |
|
Previously presented preliminary findings of this work in a poster abstract at the 55th annual meeting of the American Society of Dermatopathology on November 9, 2018, in Chicago, Illinois. |
|
Disclaimer: The content in this report is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. |
Vol 81 - N° 5
P. 1157-1164 - novembre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?